MT 7529

Drug Profile

MT 7529

Alternative Names: H7 vaccine; H7 VLP influenza vaccine - Medicago; H7N9 vaccine - Medicago; H7N9 VLP vaccine with GLA adjuvant - Medicago; MT-7529; Plant-based H7N9 VLP vaccine - Medicago; Plant-made H7 virus-like particle influenza vaccine - Medicago

Latest Information Update: 06 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medicago
  • Class Influenza A virus H7N9 vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus H7N9 subtype

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Influenza-A virus H7N9 subtype(Prevention) in Canada (IM, Injection)
  • 27 Jul 2018 MT 7529 is still in phase I trials for Influenza-A virus H7N9 subtype (Prevention)
  • 31 Jul 2015 Phase I development is ongoing Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top